PMID- 32334592
OWN - NLM
STAT- MEDLINE
DCOM- 20200825
LR  - 20200825
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Apr 25
TI  - Comparison of the effects of twice-daily exenatide and insulin on carotid 
      intima-media thickness in type 2 diabetes mellitus patients: a 52-week 
      randomized, open-label, controlled trial.
PG  - 48
LID - 10.1186/s12933-020-01014-7 [doi]
LID - 48
AB  - BACKGROUND: Exenatide, a glucagon like peptide 1 analog, has been suggested to 
      reduce the cardiovascular disease risk factors, such as body weight, blood 
      pressure and subclinical atherosclerosis in patients with type 2 diabetes 
      mellitus (T2DM). This was the first randomized, open-label, controlled trial to 
      compare the effects of exenatide versus insulin on subclinical atherosclerosis, 
      as assessed by carotid-intima media thickness (CIMT), in patients with T2DM. 
      METHODS: A total of 66 patients with T2DM admitted from March 10, 2015 to June 
      20, 2017 in the Department of Endocrinology, Beijing Hospital were randomized to 
      receive twice-daily exenatide or aspartate 70/30 insulin for 52 weeks. The 
      primary endpoint was change from baseline in CIMT, and secondary endpoints 
      included changes at week 52 from baseline in body weight, glycemic markers, lipid 
      metabolism markers, blood pressure, C-reactive protein, fibrinogen, 
      8-hydroxydeoxyguanosine, irisin, and brain natriuretic peptide. RESULTS: 
      Exenatide more significantly reduced the CIMT from baseline compared with insulin 
      after 52 weeks, with a mean difference of - 0.14 mm (95% interval confidence: 
      - 0.25, - 0.02; P = 0.016). Weight and body mass index were both significantly 
      reduced in the exenatide group over 52 weeks. Exenatide reduced total lipoprotein 
      and low-density lipoprotein cholesterol levels more significantly than insulin at 
      weeks 16 and 40. Correlation analyses showed that CIMT was positively correlated 
      with low-density lipoprotein cholesterol. CONCLUSIONS: Twice-daily exenatide 
      could prevent atherosclerosis progression in patients with T2DM over a 52-week 
      treatment period compared with insulin therapy. Trial registration Chinese 
      Clinical Trial Registry ChiCTR-1800015658.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology; 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate 
      School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 
      100730, P. R. China.
FAU - Xian, Tong-Zhang
AU  - Xian TZ
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology; 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua 
      Road, Dong Dan, Beijing, 100730, P. R. China.
FAU - Wu, Ming-Xiao
AU  - Wu MX
AD  - Department of Ultrasound, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua 
      Road, Dong Dan, Beijing, 100730, P. R. China.
FAU - Li, Chen
AU  - Li C
AD  - Department of Ultrasound, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua 
      Road, Dong Dan, Beijing, 100730, P. R. China.
FAU - Pan, Qi
AU  - Pan Q
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology; 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua 
      Road, Dong Dan, Beijing, 100730, P. R. China. panqi621@126.com.
FAU - Guo, Li-Xin
AU  - Guo LX
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology; 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate 
      School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 
      100730, P. R. China. glx1218@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR-1800015658
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200425
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 9P1872D4OL (Exenatide)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Beijing
MH  - Blood Glucose/drug effects/metabolism
MH  - Carotid Arteries/diagnostic imaging/*drug effects
MH  - Carotid Artery Diseases/diagnostic imaging/*drug therapy
MH  - *Carotid Intima-Media Thickness
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Exenatide/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Incretins/*administration & dosage/adverse effects
MH  - Insulin Aspart/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC7183674
OTO - NOTNLM
OT  - Carotid intima-media thickness
OT  - Exenatide
OT  - Insulin
OT  - Low-density lipoprotein cholesterol
COIS- The authors declare that they have no competing interests.
EDAT- 2020/04/27 06:00
MHDA- 2020/08/26 06:00
PMCR- 2020/04/25
CRDT- 2020/04/27 06:00
PHST- 2019/09/25 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/04/27 06:00 [entrez]
PHST- 2020/04/27 06:00 [pubmed]
PHST- 2020/08/26 06:00 [medline]
PHST- 2020/04/25 00:00 [pmc-release]
AID - 10.1186/s12933-020-01014-7 [pii]
AID - 1014 [pii]
AID - 10.1186/s12933-020-01014-7 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2020 Apr 25;19(1):48. doi: 10.1186/s12933-020-01014-7.